Ratings Bioretec Oy

Equities

BRETEC

FI4000480454

Market Closed - Nasdaq Helsinki Other stock markets 16:24:17 15/05/2024 BST			5-day change	1st Jan Change
2.72 ^EUR	+1.12%		+0.37%	+13.33%

04-05	Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors	CI
03-22	Finland's Bioretec Gets US Patent Allowance for Magnesium Alloy Composition	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
BIORETEC OY	+13.33%	59.18M	-
SHOCKWAVE MEDICAL, INC.	+73.63%	12.43B	B-
PENUMBRA, INC.	-18.62%	8.09B	C+
MASIMO CORPORATION	-0.90%	6.12B	C-
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+14.66%	5.59B	D+
GETINGE AB	-14.69%	5.47B	B
APT MEDICAL INC.	+39.93%	5.23B	-
ASAHI INTECC CO., LTD.	-13.09%	4.1B	B-
INARI MEDICAL, INC.	-27.62%	2.65B	C
SKAN GROUP AG	+1.36%	1.99B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes